US7897159B2 - Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer - Google Patents

Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer Download PDF

Info

Publication number
US7897159B2
US7897159B2 US12/123,360 US12336008A US7897159B2 US 7897159 B2 US7897159 B2 US 7897159B2 US 12336008 A US12336008 A US 12336008A US 7897159 B2 US7897159 B2 US 7897159B2
Authority
US
United States
Prior art keywords
cancer
parapoxvirus ovis
agent
group
parapoxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/123,360
Other versions
US20090035269A1 (en
Inventor
Olaf Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US7897159(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Assigned to AICURIS GMBH & CO. KG reassignment AICURIS GMBH & CO. KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WEBER, OLAF
Publication of US20090035269A1 publication Critical patent/US20090035269A1/en
Application granted granted Critical
Publication of US7897159B2 publication Critical patent/US7897159B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Definitions

  • the invention relates to the production of a pharmaceutical composition for treating cancer, and to a method for treating a patient afflicted with cancer.
  • virus-based therapies holds some promise (1).
  • Viruses have evolved to infect cells and often destroy these cells through diverse mechanisms. Although a number of viruses have been used in the clinic so far, this approach has suffered from toxicity, infection of unrelated tissues, immunological side effects and, therefore, was abandoned (2).
  • recombinant DNA technology offered new possibilities to use viruses in therapeutic approaches.
  • Current attempts use replication-selective viruses (reviewed in 1). Such viruses should replicate selectively in dividing cells (3).
  • these viruses may rapidly spread in cell-culture monolayers, spread within solid tumors remains an unsolved problem (1).
  • Interferon- ⁇ IFN- ⁇
  • classical chemotherapeutics i.e., cisplatin, vinclesine and dacarbacine.
  • the combination of biologicals and cytotoxic chemotherapeutics is called biochemotherapy.
  • responder rates are up to 66% and, therefore, superior compared to cytotoxic chemotherapy (5).
  • the present invention is therefore based on the technical problem of providing a therapeutic method which not only reduces the tumor burden of patients more effectively compared to cytotoxic chemotherapy but also provides a therapeutic method for the reconstitution of the immune system after cytotoxic chemotherapy.
  • This therapeutic method should not only have fewer or no undesirable side effects, it also should be superior to current therapies.
  • the present invention relates to:
  • Parapoxvirus ovis in combination with at least one additional anticancer agent for the preparation of a medicament for treating cancer.
  • the invention furthermore relates to the use of Parapoxvirus ovis for the production of a medicament for treating cancer in combination with at least one additional anticancer agent.
  • Another aspect of the invention relates to the use of Parapoxvirus ovis for treating a patient afflicted with cancer, wherein at least one additional anticancer agent is given to said patient to treat cancer.
  • the invention relates to methods of treatment of cancer, in which Parapoxvirus ovis is administered in combination with other anticancer agents.
  • Parapoxvirus ovis is understood to be Parapoxvirus ovis strain D1701, NZ-2, NZ-7, NZ-10 or orf-11.
  • the invention also relates to the use of derivatives of the abovementioned Parapoxvirus ovis obtained by passaging or adaptation using suitable cell systems such as for example human cells such as WI-38, MRC-5, monkey cells, e.g., Vero cells, bovine cells, such as for example BL-K13A47/Reg or MDBK, and ovine cells such as MDOK, in combination with substances which are effective in anticancer therapy for the production of medicaments against cancer in humans and animals.
  • suitable cell systems such as for example human cells such as WI-38, MRC-5, monkey cells, e.g., Vero cells, bovine cells, such as for example BL-K13A47/Reg or MDBK, and ovine cells such as MDOK
  • parts or fragments of a virus are understood to be genomic or subgenomic fragments of the whole virus or of its genomic nucleic acid, or other components of the virus, which are expressed by means of suitable vectors such as vaccinia viruses in suitable systems such as fibroblast cell cultures.
  • suitable vectors such as vaccinia viruses in suitable systems such as fibroblast cell cultures.
  • the parts or fragments of the Parapoxvirus ovis according to the invention are purified by conventional methods, such as for example by filtration or chromatography.
  • the parts or fragments of the Parapoxvirus ovis according to the invention are produced by recombination by methods known to the skilled man.
  • cancer is all human and animal diseases associated with proliferating or resting tumors.
  • the anticancer agent is a cytotoxic agent.
  • the present invention also relates to a use according to item 1, wherein the cancer is melanoma, breast cancer, prostate cancer, lung cancer, colorectal cancer, liver cancer or metastatic disease of one or more of the primary cancer.
  • the present invention also relates to the use according item 1 or 2, wherein the Parapoxvirus ovis is Parapoxvirus ovis strain D1701, NZ-2, NZ-7, NZ-10 or orf-11.
  • the Parapoxvirus ovis is a Parapoxvirus obtained by passaging of these strains.
  • the present invention also relates to the use according to one of the items 1 to 3, wherein the Parapoxvirus ovis is present in an inactivated form.
  • the inactivation of the Parapoxvirus is carried out by virus inactivation methods known to the skilled man.
  • the Parapoxvirus ovis is inactivated by the method described in European Patent No. EP-B1-0312839.
  • the present invention also relates to the use according to one of the items 1 to 4, wherein the treatment of cancer produces a reduction of tumor size of patients, i.e., the medicament causes a reduction of the tumor size or mass, respectively.
  • the present invention also relates to the use according to one of the items 1 to 5, wherein the treatment of cancer reduces the number and size of metastases of the primary tumors as measured by procedures known to the skilled man.
  • the present invention also relates to the use according to one of the abovementioned items 1 to 6, wherein the anticancer agent is selected from the group consisting of asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycin), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methothrexate, mitomycinC, mitoxantrone, prednisolone, prednisone, precarbazine, raloxifen, streptozocin, tam
  • the pharmaceutical composition of the present invention may be administered in oral forms, such as, without limitation, normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions. They may also be administered in parental forms, such as, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, intratumoral and the like forms well-known to those of ordinary skill in the pharmaceutical arts.
  • the pharmaceutical composition of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal delivery systems well-known to those of ordinary skilled in the art.
  • the dosage regimen with the use of the pharmaceutical composition of the present invention is selected by one of ordinary skill in the arts, in view of a variety of factors, including, without limitation, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed.
  • compositions of the present invention are preferably formulated prior to administration and include one or more pharmaceutically acceptable excipients.
  • Excipients are inert substances such as, without limitations, carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
  • the formulation may be in unit dosage form, which is a physically discrete unit containing a unit dose, suitable for administration in human or other mammals.
  • a unit dosage form can be a capsule or tablets, or a number of capsules or tablets.
  • a “unit dose” is a predetermined quantity of the active pharmaceutical composition of the present invention, calculated to produce the desired therapeutic effect, in association with one or more excipients. Dosages will vary from about 10 3 to about 10 12 physical number of viral particles per application or will be based an physical number of particles/kg/day.
  • compositions of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. Where delivery is via transdermal forms, of course, administration is preferably continuous.
  • FIG. 1 shows that the anti-tumor activity of a Parapoxvirus ovis (PPVO) and Taxol combination is superior to a monotherapy with either taxol or PPVO in an MDAMB 231 breast cancer model in nude mice.
  • Paclitaxel (Taxol®, Bristol Myers Squibb) was administered at 7.5 mg/kg/day i.v. on three consecutive days starting day 10.
  • MDA-MB-231 human breast carcinoma cells (ATCC # HTB26) were cultured in standard universal growth medium (UM: DMEM, 10% FBS, 10 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin) at 37° C. in 5% CO 2 in a humidified incubator.
  • the cells were harvested by trypsinization, washed, counted, adjusted to 2.5 ⁇ 10 7 cells/ml with ice cold phosphate-buffered saline (PBS), and subsequently stored on ice until transplantation.
  • PBS ice cold phosphate-buffered saline
  • Approximately 5 ⁇ 10 6 cells in a total volume of 0.2 ml PBS are injected subcutaneously (s.c.) in the flank region.
  • a single dose of PPVO (1 ⁇ 10 6 TCID 50 ) was administered day 13 after transplantation intraperitoneally.
  • the administration of Paclitaxel and PPVO according to the dosage regimen applied to groups two and three was combined. For reasons of animal welfare, animals were sacrificed when the tumors reached approximately 10-15% of the mouse body weight or when the tumors scabbed or ulcerated.
  • the mean tumor size is clearly reduced in group four ( ) if compared to group two ( ) or group three ( ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a method for the production of a pharmaceutical composition for treating cancer by combining Parapoxvirus ovis with at least one anticancer agent. The invention furthermore relates to a method for treating a patient afflicted with cancer comprising the administration of Parapoxvirus ovis in combination with at least one anticancer agent.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS
This application is a continuation of co-pending international patent application PCT/EP2006/009855 filed on Oct. 12, 2006 and designating the U.S., and claims priority of European patent application EP 05 025 600.7 filed on Nov. 24, 2005. The contents of the above-referenced applications are incorporated herein by this reference in their entirety.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to the production of a pharmaceutical composition for treating cancer, and to a method for treating a patient afflicted with cancer.
2. Related Prior Art
In the search for novel cancer therapies that can be used in conjunction with existing treatments, the use of virus-based therapies holds some promise (1). Viruses have evolved to infect cells and often destroy these cells through diverse mechanisms. Although a number of viruses have been used in the clinic so far, this approach has suffered from toxicity, infection of unrelated tissues, immunological side effects and, therefore, was abandoned (2). However, recombinant DNA technology offered new possibilities to use viruses in therapeutic approaches. Current attempts use replication-selective viruses (reviewed in 1). Such viruses should replicate selectively in dividing cells (3). However, although these viruses may rapidly spread in cell-culture monolayers, spread within solid tumors remains an unsolved problem (1).
The use of inactivated Parapoxvirus ovis for cancer therapies has been suggested previously (4).
Interferon-α (IFN-α) has previously been investigated with classical chemotherapeutics, i.e., cisplatin, vinclesine and dacarbacine. The combination of biologicals and cytotoxic chemotherapeutics is called biochemotherapy. After biochemotherapy, responder rates are up to 66% and, therefore, superior compared to cytotoxic chemotherapy (5).
The use of inactivated viruses for biochemotherapy in cancer therapies has not been reported.
As is clear from the abovementioned prior art, no therapeutic method has so far been disclosed which uses an inactivated virus as an immunomodulating agent and a classical cytotoxic chemotherapeutic agent as a biochemotherapy for cancer.
SUMMARY OF THE INVENTION
The present invention is therefore based on the technical problem of providing a therapeutic method which not only reduces the tumor burden of patients more effectively compared to cytotoxic chemotherapy but also provides a therapeutic method for the reconstitution of the immune system after cytotoxic chemotherapy. This therapeutic method should not only have fewer or no undesirable side effects, it also should be superior to current therapies.
The present invention relates to:
1. The use of Parapoxvirus ovis in combination with at least one additional anticancer agent for the preparation of a medicament for treating cancer. The invention furthermore relates to the use of Parapoxvirus ovis for the production of a medicament for treating cancer in combination with at least one additional anticancer agent. Another aspect of the invention relates to the use of Parapoxvirus ovis for treating a patient afflicted with cancer, wherein at least one additional anticancer agent is given to said patient to treat cancer. Furthermore, the invention relates to methods of treatment of cancer, in which Parapoxvirus ovis is administered in combination with other anticancer agents.
According to the invention Parapoxvirus ovis is understood to be Parapoxvirus ovis strain D1701, NZ-2, NZ-7, NZ-10 or orf-11.
The invention also relates to the use of derivatives of the abovementioned Parapoxvirus ovis obtained by passaging or adaptation using suitable cell systems such as for example human cells such as WI-38, MRC-5, monkey cells, e.g., Vero cells, bovine cells, such as for example BL-K13A47/Reg or MDBK, and ovine cells such as MDOK, in combination with substances which are effective in anticancer therapy for the production of medicaments against cancer in humans and animals.
In addition, the invention relates to the use of parts or fragments of the abovementioned Parapoxvirus ovis and their passaging and adaption variants in combination with substances which are effective in anticancer therapy. According to the invention, parts or fragments of a virus are understood to be genomic or subgenomic fragments of the whole virus or of its genomic nucleic acid, or other components of the virus, which are expressed by means of suitable vectors such as vaccinia viruses in suitable systems such as fibroblast cell cultures. In a preferred variant the parts or fragments of the Parapoxvirus ovis according to the invention are purified by conventional methods, such as for example by filtration or chromatography. In another preferred variant the parts or fragments of the Parapoxvirus ovis according to the invention are produced by recombination by methods known to the skilled man. According to the invention, cancer is all human and animal diseases associated with proliferating or resting tumors.
In a preferred variant of the invention the anticancer agent is a cytotoxic agent.
2. The present invention also relates to a use according to item 1, wherein the cancer is melanoma, breast cancer, prostate cancer, lung cancer, colorectal cancer, liver cancer or metastatic disease of one or more of the primary cancer.
3. The present invention also relates to the use according item 1 or 2, wherein the Parapoxvirus ovis is Parapoxvirus ovis strain D1701, NZ-2, NZ-7, NZ-10 or orf-11. In a further variant of the invention the Parapoxvirus ovis is a Parapoxvirus obtained by passaging of these strains.
4. The present invention also relates to the use according to one of the items 1 to 3, wherein the Parapoxvirus ovis is present in an inactivated form. The inactivation of the Parapoxvirus is carried out by virus inactivation methods known to the skilled man. In a preferred variant the Parapoxvirus ovis is inactivated by the method described in European Patent No. EP-B1-0312839.
5. The present invention also relates to the use according to one of the items 1 to 4, wherein the treatment of cancer produces a reduction of tumor size of patients, i.e., the medicament causes a reduction of the tumor size or mass, respectively.
6. The present invention also relates to the use according to one of the items 1 to 5, wherein the treatment of cancer reduces the number and size of metastases of the primary tumors as measured by procedures known to the skilled man.
7. The present invention also relates to the use according to one of the abovementioned items 1 to 6, wherein the anticancer agent is selected from the group consisting of asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycin), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methothrexate, mitomycinC, mitoxantrone, prednisolone, prednisone, precarbazine, raloxifen, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, amnogluthethimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2′,2′-difluorodeoxycytidine, docetaxel, erythrohydroxynonyl adenine, ethinyl estradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel, pentstatin, PALA, plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, and vinorelbine, oxaliplatin, gemcitabine, capecitabine, epothilone and its natural or synthetic derivatives, tositumomab, trabedectin, and temozolomide, trastuzumab, cetuximab, bevacizumab, pertuzumab, ZD-1839 (Iressa), OSI-774 (Tarceva), CI-1033, GW-2016, CP-724,714, HKI-272, EKB-569, STI-571 (Gleevec), PTK-787, SU-11248, ZD-6474, AG-13736, KRN-951, CP-547, 632, CP-673,451 and sorafenib.
The pharmaceutical composition of the present invention may be administered in oral forms, such as, without limitation, normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions. They may also be administered in parental forms, such as, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, intratumoral and the like forms well-known to those of ordinary skill in the pharmaceutical arts. The pharmaceutical composition of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal delivery systems well-known to those of ordinary skilled in the art.
The dosage regimen with the use of the pharmaceutical composition of the present invention is selected by one of ordinary skill in the arts, in view of a variety of factors, including, without limitation, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed.
The pharmaceutical compositions of the present invention are preferably formulated prior to administration and include one or more pharmaceutically acceptable excipients. Excipients are inert substances such as, without limitations, carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
The formulation may be in unit dosage form, which is a physically discrete unit containing a unit dose, suitable for administration in human or other mammals. A unit dosage form can be a capsule or tablets, or a number of capsules or tablets. A “unit dose” is a predetermined quantity of the active pharmaceutical composition of the present invention, calculated to produce the desired therapeutic effect, in association with one or more excipients. Dosages will vary from about 103 to about 1012 physical number of viral particles per application or will be based an physical number of particles/kg/day.
The pharmaceutical compositions of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. Where delivery is via transdermal forms, of course, administration is preferably continuous.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows that the anti-tumor activity of a Parapoxvirus ovis (PPVO) and Taxol combination is superior to a monotherapy with either taxol or PPVO in an MDAMB 231 breast cancer model in nude mice. Paclitaxel (Taxol®, Bristol Myers Squibb) was administered at 7.5 mg/kg/day i.v. on three consecutive days starting day 10. A single dose of PPVO (1×106 TCID50) or the respective placebo was administered day 13 after transplantation intraperitoneally (n=10 mice/group).
 DESCRIPTION OF PREFERRED EMBODIMENTS
MDA-MB-231 human breast carcinoma cells (ATCC # HTB26) were cultured in standard universal growth medium (UM: DMEM, 10% FBS, 10 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin) at 37° C. in 5% CO2 in a humidified incubator. The cells were harvested by trypsinization, washed, counted, adjusted to 2.5×107 cells/ml with ice cold phosphate-buffered saline (PBS), and subsequently stored on ice until transplantation. Approximately 5×106 cells in a total volume of 0.2 ml PBS are injected subcutaneously (s.c.) in the flank region. Eight-to-ten week-old female NCr nude mice (Taconic, Germantown, N.Y.) with an average body mass of about 20-25 g were used for the experiments. Tumor measurements were performed 10 days after transplantation. Tumor sizes were calculated using the formula (a×b×b)/2. Thereafter the mice were randomized and divided into several groups that reflect different treatments (n=10 mice/group). In the first group the mice only received PBS as a control approach. In the second group Paclitaxel (Taxol®, Bristol Myers Squibb) was administered at 7.5 mg/kg/day i.v. on three consecutive days starting day 10. In the third group a single dose of PPVO (1×106 TCID50) was administered day 13 after transplantation intraperitoneally. In the fourth group the administration of Paclitaxel and PPVO according to the dosage regimen applied to groups two and three was combined. For reasons of animal welfare, animals were sacrificed when the tumors reached approximately 10-15% of the mouse body weight or when the tumors scabbed or ulcerated.
As it can be seen in FIG. 1 the mean tumor size is clearly reduced in group four (
Figure US07897159-20110301-P00001
) if compared to group two (
Figure US07897159-20110301-P00002
) or group three (
Figure US07897159-20110301-P00003
).
Therefore, the inventors clearly demonstrated for the first time that the administration of a combination of Parapoxvirus ovis (PPVO) and a conventional anticancer agent is superior to a monotherapy with either the anticancer agent or PPVO alone.
REFERENCES
  • 1. D. Kirn, R. J. Martuza, J. Zwiebel, Nat. Med. 7, 781 (2001)
  • 2. C. M. Southam, NY Acad. Sci. 22, 656 (1960)
  • 3. R. L. Martuza, A. Malick, J. M. Markert, K. L. Ruffner, D. M. Coen, Science 252, 856 (1991)
  • 4. O. Weber et al. WO 02/04002
  • 5. S. S. Legha J. Clin. Oncol. 14, 7 (1996) FSHβ

Claims (12)

1. A method for the production of a pharmaceutical composition for treating cancer, comprising the provision of Parapoxvirus ovis and at least one anti-cancer agent, and the formulation of said Parapoxvirus ovis in combination with said at least one anti-cancer agent into a pharmaceutical acceptable carrier, wherein said anti-cancer agent is a cytotoxic agent.
2. The method according to claim 1, wherein said cancer is selected from the group consisting of: melanoma, breast cancer, prostate cancer, lung cancer, colorectal cancer, liver cancer, bladder cancer, cancer of the endocrine system, cancer of the nervous system, lymphoma and metastatic disease of the respective primary cancer.
3. The method according to claim 1, wherein said Parapoxvirus ovis is selected from the group consisting of: Parapoxvirus ovis strains D1701, NZ-2, NZ-7, NZ-10, orf-11, and a Parapoxvirus ovis strain obtained by any passaging of before identified strains.
4. The method according to claim 1, wherein said Parapoxvirus ovis is present in an inactivated form.
5. The method according to claim 1, wherein said pharmaceutical composition causes a reduction of tumor size or tumor mass.
6. The method according to claim 1, wherein said anti-cancer agent is selected from the group consisting of: vinblastine, vincristine, docetaxel, and paclitaxel.
7. A method for treating a patient afflicted with cancer, comprising the step of the administration of Parapoxvirus ovis in combination with at least one anti-cancer agent, wherein said anti-cancer agent is a cytotoxic agent.
8. The method of claim 7, wherein said cancer is selected from the group consisting of: melanoma, breast cancer, prostate cancer, lung cancer, colorectal cancer, liver cancer, bladder cancer, cancer of the endocrine system, cancer of the nervous system, lymphoma, and metastatic disease of the respective primary cancer.
9. The method of claim 7, wherein said Parapoxvirus ovis is selected from the group consisting of: Parapoxvirus ovis strains D1701, NZ-2, NZ-7, NZ-10, orf-11, and a Parapoxvirus ovis strain obtained by any passaging of before identified strains.
10. The method of claim 7, wherein said Parapoxvirus ovis is present in an inactivated form.
11. The method of claim 7, wherein said administration causes a reduction of tumor size or tumor mass.
12. The method of claim 7, wherein said anti-cancer agent is selected from the group consisting of: vinblastine, vincristine, and paclitaxel.
US12/123,360 2005-11-24 2008-05-19 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer Active 2027-05-29 US7897159B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05025600 2005-11-24
EP05025600 2005-11-24
EP05025600.7 2005-11-24
PCT/EP2006/009855 WO2007059821A1 (en) 2005-11-24 2006-10-12 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009855 Continuation WO2007059821A1 (en) 2005-11-24 2006-10-12 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
US20090035269A1 US20090035269A1 (en) 2009-02-05
US7897159B2 true US7897159B2 (en) 2011-03-01

Family

ID=37654955

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/123,360 Active 2027-05-29 US7897159B2 (en) 2005-11-24 2008-05-19 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Country Status (14)

Country Link
US (1) US7897159B2 (en)
EP (1) EP1951274B1 (en)
JP (1) JP5164849B2 (en)
CN (1) CN101312737B (en)
AR (1) AR057922A1 (en)
AT (1) ATE450266T1 (en)
CA (1) CA2630833C (en)
DE (1) DE602006010902D1 (en)
DK (1) DK1951274T3 (en)
ES (1) ES2335308T3 (en)
PL (1) PL1951274T3 (en)
PT (1) PT1951274E (en)
TW (1) TWI415617B (en)
WO (1) WO2007059821A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139558B2 (en) 2007-10-17 2015-09-22 Wyeth Llc Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9211291B2 (en) 2009-04-06 2015-12-15 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US9265784B2 (en) 2008-08-04 2016-02-23 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US9511063B2 (en) 2008-06-17 2016-12-06 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
US10596162B2 (en) 2005-02-03 2020-03-24 Wyeth Llc Method for treating gefitinib resistant cancer
US10729672B2 (en) 2005-11-04 2020-08-04 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069455A2 (en) 1999-05-14 2000-11-23 Bayer Aktiengesellschaft Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
WO2002004002A2 (en) 2000-07-11 2002-01-17 Bayer Aktiengesellschaft Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
WO2003006654A2 (en) 2001-06-13 2003-01-23 Bayer Healthcare Ag Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816139A1 (en) 1987-10-17 1989-04-27 Bayer Ag METHOD FOR PRODUCING PARAMUNITY INDUCERS
AR035227A1 (en) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc USE OF A CHEMOTHERAPEUTIC AGENT FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE SENSITIZATION OF NEOPLASSIC CELLS RESISTANT TO CHEMOTHERAPEUTIC AGENTS WITH REOVIRUS
EP2269618A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069455A2 (en) 1999-05-14 2000-11-23 Bayer Aktiengesellschaft Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
US20060008471A1 (en) 1999-05-14 2006-01-12 Bayer Aktiengesellschaft Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
WO2002004002A2 (en) 2000-07-11 2002-01-17 Bayer Aktiengesellschaft Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
US20030021769A1 (en) * 2000-07-11 2003-01-30 Olaf Weber Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
WO2003006654A2 (en) 2001-06-13 2003-01-23 Bayer Healthcare Ag Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Cozzi et al., Curr. Med. Chem.-Anti-Cancer Agents (2004) 4:93-121.
Cozzi et al., Curr. Med. Chem.—Anti-Cancer Agents (2004) 4:93-121.
Friebe et al., Journal of Virology (2004) 78(17):9400-9411.
Glimelius et al (Acta Oncologica. 40:135-154, 2001). *
International Preliminary Report on Patentability for PCT/EP2006/009855, dated Feb. 28, 2008, 7 pages.
International Search Report for PCT/EP2006/009855, mailed on Feb. 9, 2007, 3 pages.
Kirn et al., Nature Medicine (2001) 7(7):781-787.
Martuza et al., Science (1991) 252:854-856.
Smith et al., Journal of Clinical Oncology (1996) 14:287-295.
Southam, NY Academy of Sciences (1960) 22:657-673.
Written Opinion for PCT/EP2006/009855, dated Feb. 28, 2008, 6 pages.

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596162B2 (en) 2005-02-03 2020-03-24 Wyeth Llc Method for treating gefitinib resistant cancer
US10603314B2 (en) 2005-02-03 2020-03-31 The General Hospital Corporation Method for treating gefitinib resistant cancer
US10729672B2 (en) 2005-11-04 2020-08-04 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
US9139558B2 (en) 2007-10-17 2015-09-22 Wyeth Llc Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9630946B2 (en) 2007-10-17 2017-04-25 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US10035788B2 (en) 2007-10-17 2018-07-31 Wyeth Llc Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9511063B2 (en) 2008-06-17 2016-12-06 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
US10111868B2 (en) 2008-06-17 2018-10-30 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
US9265784B2 (en) 2008-08-04 2016-02-23 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US9211291B2 (en) 2009-04-06 2015-12-15 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer

Also Published As

Publication number Publication date
PL1951274T3 (en) 2010-05-31
CA2630833A1 (en) 2007-05-31
TWI415617B (en) 2013-11-21
HK1117427A1 (en) 2009-01-16
DE602006010902D1 (en) 2010-01-14
EP1951274A1 (en) 2008-08-06
CA2630833C (en) 2015-01-06
PT1951274E (en) 2009-12-14
JP2009517347A (en) 2009-04-30
DK1951274T3 (en) 2010-02-01
TW200738250A (en) 2007-10-16
ES2335308T3 (en) 2010-03-24
CN101312737A (en) 2008-11-26
AR057922A1 (en) 2007-12-26
ATE450266T1 (en) 2009-12-15
EP1951274B1 (en) 2009-12-02
US20090035269A1 (en) 2009-02-05
JP5164849B2 (en) 2013-03-21
CN101312737B (en) 2012-11-14
WO2007059821A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
US7897159B2 (en) Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
JP7564572B2 (en) Therapeutic agent comprising isolated recombinant oncolytic vaccinia virus and NK cells, its use and kits for application thereof
US12350304B2 (en) Recombinant oncolytic virus composition and use thereof
Bouvet et al. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide
US20220339220A1 (en) Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancers
JP5037775B2 (en) Use of parapoxvirus ovis for the manufacture of antiviral drugs and medicaments against cancer
CA3097306A1 (en) Coxsackie virus b for treating tumors
CN106413726A (en) poxvirus oncolytic vector
HK1117427B (en) Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
CN111686114B (en) New application of compound I-BET-762 in preparation of drug for preventing or treating African swine fever
CN116870014B (en) Application of peimine in preparation of oncolytic virus antitumor synergist and composition containing peimine
Pan et al. Novel cancer treatment using oncolytic virus therapy
KR102737719B1 (en) Novel Lactobacillus plantarum Probio-88, extract amd composition thereof
WO2024077509A1 (en) Pharmaceutical composition for preventing and treating poxvirus infections and diseases caused thereby and use thereof
HK40008307B (en) Recombinant oncolytic virus composition and use thereof
HK40008307A (en) Recombinant oncolytic virus composition and use thereof
Martino et al. Treatment of Hepatic Abcesses in Chronic Granulomatous Disease with Granulomatous Disease with...

Legal Events

Date Code Title Description
AS Assignment

Owner name: AICURIS GMBH & CO. KG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WEBER, OLAF;REEL/FRAME:021795/0010

Effective date: 20080819

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12